latest news stock values companies glp-1 obesity cardiometabolic Some 22% of American women and 14% of men have taken GLP-1s for weight loss or for chronic conditions such as diabetes. Rebecca Diamond of Harvard University used data from the Understanding Obesity GLP-1 Market

The manufacturers of GLP1-RAs typically recommend lowering doses of insulin and insulin secretagogues at the initiation of GLP-1 RA treatment to reduce the risk of hypoglycemia

This is referred to as metabolic adaptation, which reduces GLP-1 and GIP levels and increases the orexigenic hormone ghrelin

Estrogen decline affects ghrelin and leptin signaling, making hunger harder to ignore and satiety signals weaker

Paid advertising, influencer partnerships, and viral content creation provide distribution channels that did not exist a decade ago

Blood sugar fluctuations : In patients with insulin resistance or prediabetes, GLP1 medications can cause blood sugar to drop lower than the body is accustomed to

Assuming rebates of 50% across all GLP-1 products in 2024 would mean net spending of around $14 billion in 2024